Thanks to Amgen biosim settlement, AbbVie’s $20B Humira forecast looks real

28th September 2017 Uncategorised 0

AbbVie’s assertion that Humira will sail clear for several years gained strength on Thursday as the drugmaker inked a patent settlement with Amgen, holding off that company’s biosimilar until 2023.

More: Thanks to Amgen biosim settlement, AbbVie’s B Humira forecast looks real
Source: fierce